Company Description
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers.
The company’s lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors.
It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly.
The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020.
Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2020 |
| IPO Date | Jan 9, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 79 |
| CEO | Matthew Roden |
Contact Details
Address: 17 Drydock Avenue, Suite 17-401 Boston, Massachusetts 02210 United States | |
| Phone | 617-461-4023 |
| Website | aktisoncology.com |
Stock Details
| Ticker Symbol | AKTS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0002035832 |
| CUSIP Number | 01021M104 |
| ISIN Number | US01021M1045 |
| Employer ID | 85-2584233 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Matthew Roden Ph.D. | President, Chief Executive Officer and Director |
| Todd Foley M.B.A. | Co-Founder and Chairman |
| Dr. Paul L. Feldman Ph.D. | Chief Scientific Officer |
| Dr. Akos Czibere M.D., Ph.D. | Chief Medical Officer |
| Dr. Patrick A. Baeuerle Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Kyle D. Kuvalanka | Chief Financial Officer |
| Dr. Shulamit Ron-Bigger Ph.D. | Chief Operating Officer |
| Dr. Tyler Benedum Ph.D. | Chief Technical Officer |
| Carlos Rodriguez | Executive Director of Corporate Development |
| Dr. Dasa Lipovsek Ph.D. | Vice President and Head of Lead Discovery |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2026 | 8-K | Current Report |
| Mar 30, 2026 | 8-K | Current Report |
| Mar 30, 2026 | 10-K | Annual Report |
| Jan 20, 2026 | SCHEDULE 13D | Filing |
| Jan 20, 2026 | SCHEDULE 13D | Filing |
| Jan 15, 2026 | SCHEDULE 13D | Filing |
| Jan 14, 2026 | SCHEDULE 13D | Filing |
| Jan 12, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jan 12, 2026 | 8-K | Current Report |
| Jan 9, 2026 | 424B4 | Prospectus |